Cargando…

Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan

Summary Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tshering, Dawa, Chejor, Pelden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284528/
https://www.ncbi.nlm.nih.gov/pubmed/35859611
http://dx.doi.org/10.1016/j.rcsop.2022.100156
_version_ 1784747581023191040
author Tshering, Dawa
Chejor, Pelden
author_facet Tshering, Dawa
Chejor, Pelden
author_sort Tshering, Dawa
collection PubMed
description Summary Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic.
format Online
Article
Text
id pubmed-9284528
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92845282022-07-15 Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan Tshering, Dawa Chejor, Pelden Explor Res Clin Soc Pharm Article Summary Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally. The first-ever case of COVID-19 in Bhutan was confirmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory flexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines during the pandemic. In this commentary, we discuss the regulatory flexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic. Elsevier 2022-07-15 /pmc/articles/PMC9284528/ /pubmed/35859611 http://dx.doi.org/10.1016/j.rcsop.2022.100156 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Tshering, Dawa
Chejor, Pelden
Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
title Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
title_full Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
title_fullStr Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
title_full_unstemmed Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
title_short Regulatory flexibilities and access to COVID-19 vaccines during the pandemic in Bhutan
title_sort regulatory flexibilities and access to covid-19 vaccines during the pandemic in bhutan
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284528/
https://www.ncbi.nlm.nih.gov/pubmed/35859611
http://dx.doi.org/10.1016/j.rcsop.2022.100156
work_keys_str_mv AT tsheringdawa regulatoryflexibilitiesandaccesstocovid19vaccinesduringthepandemicinbhutan
AT chejorpelden regulatoryflexibilitiesandaccesstocovid19vaccinesduringthepandemicinbhutan